

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
**RLL-256.1CIPUS**

In Re Application Of: **SALMAN et al.**

Application No. <b>10/520,572</b>	Filing Date <b>1/19/2006</b>	Examiner <b>Unknown</b>	Customer No. <b>26815</b>	Group Art Unit <b>1626</b>	Confirmation No. <b>5946</b>
--------------------------------------	---------------------------------	----------------------------	------------------------------	-------------------------------	---------------------------------

Title: **AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS**

Address to:  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

**OR**

☐ the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
RLL-256.1CIPUS

In Re Application of: **SALMAN et al.**

Application No. 10/520,571	Filing Date 1/19/2006	Examiner Unknown	Customer No. 26815	Group Art Unit 1626	Confirmation No. 5946
-------------------------------	--------------------------	---------------------	-----------------------	------------------------	--------------------------

Title: **AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912  
as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**


**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa	
_____ (Date)	
_____ Signature	
_____ Typed or Printed Name of Person Signing Certificate	

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on	
_____ July 27, 2007 (Date)	
_____ Signature of Person Mailing Correspondence Christine Kenedy-Renner	
_____ Typed or Printed Name of Person Mailing Certificate	

\*This certificate may only be used if paying by deposit account.



Signature

Dated: July 27, 2007

George E. Heibel, Esq.  
Reg No. 42,648

CC:

**INFORMATION DISCLOSURE CITATION**Docket No.:  
RLL-256.1CIPUS

Serial No.: 10/520,572

Applicants: MEHTA et al.

Filed: 1/19/2006

Group: 2183

JUL 30 2007 SUPPLEMENTAL

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	S1A1	5,179,108	1/12/1993	George et al.	514	319	
	S1A2	2003/0105071	6/5/2003	Cuny et al.	514	210.2	
	S1A3	2003/0162780	8/28/2003	Brotherton-Pleiss et al.	514	235.5	
	S1A4	2003/0171362	9/11/2003	Madera et al.	514	218	
	S1A5	7,232,835	6/19/2007	Mehta et al.	514	323	

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES   NO	
	S1B1	WO 99/43657	9/2/1999	PCT	C07D	211/26		
	S1B2	WO 01/47893	7/5/2001	PCT	C07D	221/24		
	S1B3	WO 01/090082	11/29/2001	PCT	C07D	241/08		
	S1B4	WO 03/033495	4/24/2003	PCT	C07D	453/02		
	S1B5	WO 03/048124	6/12/2003	PCT	C07D	211/26		
	S1B6	WO 03/048125	6/12/2003	PCT	C07D	211/58		
	S1B7	WO 04/067510	8/12/2004	PCT	C07D	209/52		
	S1B8	WO 04/069835	8/19/2004	PCT	C07D	471/08		
	S1B9	WO 04/089363	10/21/2004	PCT	A61K	31/403		
	S1B10	WO 04/089898	10/21/2004	PCT	C07D	209/52		
	S1B11	WO 04/089899	10/21/2004	PCT	C07D	209/52		
	S1B12	WO 2005/092341	10/6/2005	PCT	A61K	31/496		
	S1B13	WO 2005/003587	1/12/2006	PCT	A61K	9/16		
	S1B14	WO 2006/035282	4/6/2006	PCT	A61K	31/439		

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b>  SUPPLEMENTAL	Docket No.: RLL-256.1CIPUS	Serial No.: 10/520,572
	Applicants: MEHTA et al.	
	Filed: 1/19/2006	Group: 2183

	S1B15	WO 2006/064304	6/22/2006	PCT	C07D	209/52	

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

	S1C1	Kaiser et al, "Synthesis and Antimuscarinic Activity of Some 1-Cycloalkyl-1-hydroxy-1-phenyl-3-(4-substituted piperaziny)-2-propanones and Related Compounds", <i>Journal of Medicinal Chemistry</i> , <u>36</u> (5):610-616 (1993)
	S1C2	Carter et al, "Analogues of Oxybutynin. Synthesis and Antimuscarinic and Bladder Activity of Some Substituted 7-Amino-1-hydroxy-5-heptyn-2-ones and Related Compounds", <i>Journal of Medicinal Chemistry</i> , <u>34</u> (10):3065-3074 (1991)
	S1C3	Morissette et al, "High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids", <i>Advanced Drug Delivery Reviews</i> , <u>56</u> :275-300 (2004)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	